- The company offers a simple, AI-powered platform that helps providers identify their most valuable services, bringing clarity to complex insurance contracts, and highlighting where clinics can optimize revenue.
- The platform’s AI analytics help to identify high-risk patients and close care gaps efficiently, while letting providers track financial performance over time, aligning income with quality of care.
- Adageis continues to grow and expects to cover 580,000 patient lives by Q2 2025 and reach $100,000 in monthly recurring revenue.
As healthcare shifts further toward value-based care, one challenge continues to frustrate providers: understanding how care quality translates into financial outcomes. Adageis, a growing healthcare technology company with a patented AI-driven platform, is offering providers tools that both simplify operations and improve financial performance under value-based care models.
The platform, rebranded as a fintech AI solution, focuses on helping providers understand how their clinical decisions tie directly to revenue. According to Adageis, three central benefits stand out…
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN